Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News

Table of Contents

What We're Reading

  • What We're Reading
    Article Recommendations from Our Deputy and Senior Editors
    Cancer Immunol Res October 1 2016 4 (10) 813-813;

Milestones in Cancer Immunology

  • Milestones in Cancer Immunology | Free Article
    2016 William B. Coley Awards
    Cancer Immunol Res October 1 2016 4 (10) 814-814; DOI:10.1158/2326-6066.CIR-16-0224

Cancer Immunology Miniatures

  • Cancer Immunology Miniatures
    Correlation of PD-L1 Surface Expression on Leukemia Cells with the Ratio of PD-L1 mRNA Variants and with Electrophoretic Mobility
    Barbora Brodská, Petra Otevřelová and Kateřina Kuželová
    Cancer Immunol Res October 1 2016 4 (10) 815-819; DOI:10.1158/2326-6066.CIR-16-0063

    PD-L1 is a cell surface ligand negatively regulating immune responses. A simple PCR-based method that assesses PD-L1 surface expression is described that overcomes some obstacles to the use of PD-L1 as a prognostic marker and therapeutic target in leukemia.

  • Cancer Immunology Miniatures
    Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups
    Guillermo de Velasco, Diana Miao, Martin H. Voss, A. Ari Hakimi, James J. Hsieh, Nizar M. Tannir, Pheroze Tamboli, Leonard J. Appleman, W. Kimryn Rathmell, Eliezer M. Van Allen and Toni K. Choueiri
    Cancer Immunol Res October 1 2016 4 (10) 820-822; DOI:10.1158/2326-6066.CIR-16-0110

    mRCC patients were assessed for mutational load and expression of active tumor microenvironment markers to find correlates with MSKCC risk prognostic classifications. No correlations were found; thus, patients who would benefit most from immunotherapy are not yet identifiable.

Research Articles

  • Research Articles
    Therapeutic HPV Cancer Vaccine Targeted to CD40 Elicits Effective CD8+ T-cell Immunity
    Wenjie Yin, Dorothée Duluc, HyeMee Joo, Yaming Xue, Chao Gu, Zhiqing Wang, Lei Wang, Richard Ouedraogo, Lance Oxford, Amelia Clark, Falguni Parikh, Seunghee Kim-Schulze, LuAnn Thompson-Snipes, Sang-Yull Lee, Clay Beauregard, Jung-Hee Woo, Sandra Zurawski, Andrew G. Sikora, Gerard Zurawski and SangKon Oh
    Cancer Immunol Res October 1 2016 4 (10) 823-834; DOI:10.1158/2326-6066.CIR-16-0128

    In the U.S., HPV is responsible for more than 26,000 new cancer cases annually. A novel and effective immunotherapeutic vaccine against many types of HPV16-associated cancers was developed that supports targeting vaccines to dendritic cells via CD40.

  • Research Articles
    Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy
    David B. Page, Jianda Yuan, David Redmond, Y Hanna Wen, Jeremy C. Durack, Ryan Emerson, Stephen Solomon, Zhiwan Dong, Phillip Wong, Christopher Comstock, Adi Diab, Janice Sung, Majid Maybody, Elizabeth Morris, Edi Brogi, Monica Morrow, Virgilio Sacchini, Olivier Elemento, Harlan Robins, Sujata Patil, James P. Allison, Jedd D. Wolchok, Clifford Hudis, Larry Norton and Heather L. McArthur
    Cancer Immunol Res October 1 2016 4 (10) 835-844; DOI:10.1158/2326-6066.CIR-16-0013

    Tumor cryoablation plus immune checkpoint blockade facilitates antitumor T-cell responses (TCRs) and improves survival in mice. Deep sequencing of TCRs in human early-stage breast cancer tumors revealed T-cell clonality and density and served as a biomarker after cryo-immunotherapy.

  • Research Articles
    Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells
    Blanca Homet Moreno, Jesse M. Zaretsky, Angel Garcia-Diaz, Jennifer Tsoi, Giulia Parisi, Lidia Robert, Katrina Meeth, Abibatou Ndoye, Marcus Bosenberg, Ashani T. Weeraratna, Thomas G. Graeber, Begoña Comin-Anduix, Siwen Hu-Lieskovan and Antoni Ribas
    Cancer Immunol Res October 1 2016 4 (10) 845-857; DOI:10.1158/2326-6066.CIR-16-0060

    Although blockade of the PD-1 pathway has been successfully used to treat various cancers, how this modulates host–tumor interactions is not well understood. Additional mechanisms beyond licensing the final effector phase of killer T cells were identified.

  • Research Articles
    VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma
    Xinqi Wu, Anita Giobbie-Hurder, Xiaoyun Liao, Donald Lawrence, David McDermott, Jun Zhou, Scott Rodig and F. Stephen Hodi
    Cancer Immunol Res October 1 2016 4 (10) 858-868; DOI:10.1158/2326-6066.CIR-16-0084

    Inhibiting both CTLA-4 and VEGF can lead to favorable clinical outcomes. This treatment increased the expression of IL1α, TNFα, IP-10, and the adhesion receptors associated with increased tumor lymphocyte infiltration, and augmented humoral immune responses recognizing tumor targets.

  • Research Articles
    Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas
    Adrienne H. Long, Steven L. Highfill, Yongzhi Cui, Jillian P. Smith, Alec J. Walker, Sneha Ramakrishna, Rana El-Etriby, Susana Galli, Maria G. Tsokos, Rimas J. Orentas and Crystal L. Mackall
    Cancer Immunol Res October 1 2016 4 (10) 869-880; DOI:10.1158/2326-6066.CIR-15-0230

    The efficacy of chimeric antigen receptor (CAR)–modified T cells against solid tumors is not proven. Retinoids are clinically accessible and were found to modulate tumor myeloid-derived suppressor cells, enhancing the efficacy of CAR therapies targeting solid tumors.

  • Research Articles
    Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer
    Elizabeth Scheid, Pierre Major, Alain Bergeron, Olivera J. Finn, Russell D. Salter, Robin Eady, Bader Yassine-Diab, David Favre, Yoav Peretz, Claire Landry, Sebastien Hotte, Som D. Mukherjee, Gregory A. Dekaban, Corby Fink, Paula J. Foster, Jeffery Gaudet, Jean Gariepy, Rafick-Pierre Sekaly, Louis Lacombe, Yves Fradet and Ronan Foley
    Cancer Immunol Res October 1 2016 4 (10) 881-892; DOI:10.1158/2326-6066.CIR-15-0189

    Tumor-associated Tn-MUC1 glycosylated, but not unglycosylated, peptides, induce strong murine immunity. Tn-MUC1 vaccination in macaques and a clinical trial with a Tn-MUC-DC vaccine confirmed the safety and the superiority of Tn-MUC1 vaccination for induction of cellular immune responses.

Back to top
PreviousNext
Cancer Immunology Research: 4 (10)
October 2016
Volume 4, Issue 10
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author

Sign up for alerts

Jump to

  • What We're Reading
  • Milestones in Cancer Immunology
  • Cancer Immunology Miniatures
  • Research Articles
Advertisement
  • Most Cited
  • Most Read
Loading
  • Activity of Anti-CTLA-4 Isotypes in Antitumor Responses
  • Case Report: RNA CAR T Cells
  • PD-L1 in Triple-Negative Breast Cancer
  • Bevacizumab plus Ipilimumab
  • Vaccine-Induced Intratumoral Lymphoid Aggregates
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2019 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement